No abstract available
MeSH terms
-
Adult
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Astrocytoma / drug therapy*
-
Astrocytoma / genetics*
-
Astrocytoma / pathology
-
Astrocytoma / therapy
-
Brain Neoplasms / drug therapy*
-
Brain Neoplasms / genetics*
-
Brain Neoplasms / pathology
-
Brain Neoplasms / therapy
-
Drug Administration Schedule
-
Drug Eruptions / etiology
-
Frontal Lobe / pathology
-
Glutamic Acid
-
Humans
-
Indoles / administration & dosage
-
Indoles / adverse effects
-
Indoles / therapeutic use*
-
Magnetic Resonance Imaging
-
Male
-
Mutation*
-
Neoplasm Staging
-
Proto-Oncogene Proteins B-raf / genetics*
-
Sulfonamides / administration & dosage
-
Sulfonamides / adverse effects
-
Sulfonamides / therapeutic use*
-
Temporal Lobe / pathology
-
Treatment Outcome
-
Valine
-
Vemurafenib
-
Xanthomatosis / drug therapy*
-
Xanthomatosis / genetics*
-
Xanthomatosis / pathology
-
Xanthomatosis / therapy
Substances
-
Antineoplastic Agents
-
Indoles
-
Sulfonamides
-
Vemurafenib
-
Glutamic Acid
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf
-
Valine
Associated data
-
ClinicalTrials.gov/NCT02034110